article thumbnail

Decades-long regulatory odyssey ends with FDA nod for Fabre-Kramer's depression med Exxua

Fierce Pharma

Its label doesn't include sexual dysfunction as an adverse reaction, which is rare among antidepressants. Fabre-Kramer Pharmaceuticals' major depressive disorder (MDD) drug gepirone has been rejected by the FDA not once, not twice, but three times since the turn of the millennium.

article thumbnail

Therapeutic-first for cold agglutinin disease haemolytic anaemia

European Pharmaceutical Review

The approval is based on data from two Phase III clinical trials: CADENZA, a trial for adults with CAD without having had a blood transfusion in the past six months and CARDINAL, a 26-week open label, single-arm pivotal study in patients with CAD who have had a recent blood transfusion. CADENZA Part A trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. Most XPHOZAH-treated patients experienced mild-to-moderate reactions that resolved over time, or with dose reduction. XPHOZAH is expected to be available to eligible patients in the US in November 2023.

FDA 119
article thumbnail

STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report

STAT

and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address. Experts say that the Singulair incident highlights a flawed system, both in the U.S.

article thumbnail

US FDA approves Incyte’s merkel cell carcinoma therapy

Pharmaceutical Technology

The approval from the FDA was based on the data obtained from the multiregional, open-label, single-arm POD1UM-201 trial, conducted in metastatic or recurrent locally-advanced MCC adults who did not receive systemic therapy previously for their advanced disease. Partial response was seen in 22 patients and complete response in 12 patients.

FDA 98
article thumbnail

US FDA approves Blueprint Medicines’ indolent systemic mastocytosis therapy

Pharmaceutical Technology

With a broad indication for indolent systemic mastocytosis and a strong label, we are now engaging healthcare providers to redefine what it means for their patients to be well-controlled, as well as activating the patient community to seek out optimal care and treatment.”

FDA 98
article thumbnail

FDA grants approval to Gilead Sciences’ breast cancer therapy

Pharmaceutical Technology

The FDA approval is based on the data obtained from a global, multicentre, open-label Phase III TROPiCS-02 study conducted in 543 HR+/HER2- metastatic breast cancer patients who have received prior endocrine therapy, CDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease. “We

FDA 105